Analyst Upgrade Boosts BeOne Medicines as Brukinsa Outlook Strengthens
Jefferies upgraded BeOne Medicines, citing strong Brukinsa growth, promising cancer drugs, and potential 27% stock upside.
Already have an account? Sign in.